eISSN: 1644-4124
ISSN: 1426-3912
Central European Journal of Immunology
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
3/2015
vol. 40
 
Share:
Share:
abstract:
Clinical immunology

Influence of fingolimod on basic lymphocyte subsets frequencies in the peripheral blood of multiple sclerosis patients – preliminary study

Julia Rudnicka
,
Michał Czerwiec
,
Ewelina Grywalska
,
Dorota Siwicka-Gieroba
,
Monika Walankiewicz
,
Agnieszka Grafka
,
Michał Zgurski
,
Agata Surdacka
,
Halina Bartosik-Psujek
,
Jacek Roliński

(Cent Eur J Immunol 2015; 40 (3): 354-359)
Online publish date: 2015/10/15
View full text Get citation
 
PlumX metrics:
Background: Fingolimod is a drug administered orally to adult patients treated for relapsing remitting course of multiple sclerosis (MS). Mode of action of fingolimod is based on intense S1P1 receptor stimulation and “arresting” lymphocytes in lymphatic organs. Objective of the research was to assess changes in the frequencies of basic lymphocyte subsets in patients treated for multiple sclerosis with the use of fingolimod.

Material and methods: Study group comprised of 25 previously untreated adult patients with MS. Venous blood samples were collected from each patient before and one month, three months and six months after treatment initiation. Peripheral blood lymphocyte immunophenotype was assessed with a set of monoclonal antibodies bounded to appropriate fluorochromes and flow cytometer FACSCalibur. Statistical analysis of the results was conducted using Statistica 9.0 software.

Results: Before fingolimod administration median of lymphocyte subsets percentage in each patient was in reference range. After 1 month of treatment we noticed significant changes in frequencies of following lymphocyte subsets: NK cells – 51.22% (p = 0.016), T CD4+ cells – 11.58% (p = 0.01), T CD4+:T CD8+ cells ratio – 0.61 (p = 0.005). After 3 and 6 months of treatment there was further increase of deviation from normal state.

Conclusions: The use of fingolimod is associated with profound changes in lymphocyte subsets distribution, which might bear a risk of the development of cellular immune deficiency symptoms.

keywords:

fingolimod, multiple sclerosis, MS, lymphocytes T, T CD4+:T CD8+ cells ratio

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.